Aktiesnakken — Juni 2013
-
Genmab siver godt nok under tynd omsætning
-
Jan må gerne lige lande den DuoBody aftale nu
-
bavarain i 63,5 suk
-
ja
-
jeg er jo ingen trader.
-
men det ser jo helt skævt ud i den lige nu
-
både bava og zealna
-
zealands tech platform er ret lavt prissat
-
lom det tror jeg ikke på. Syntes der sker de rigtige ting i Zeal
-
Problemet for dem er at de har kunnet guide på royalty
-
fordi Sanofi ikke gider guide på salget
-
Sanofi kommer med update 28/6 omkring LixiLan
-
Opstart af phase III mv. timelines og sådan
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind